About Cellares
Cellares develops and manufactures cell therapies in the biotechnology sector, operating as an Integrated Development and Manufacturing Organization (IDMO). Its proprietary "Smart Factory" technology features an automated single-use cartridge system, which increases productivity and reduces costs and process failures compared to traditional methods. The company serves a range of clients, including pharmaceutical companies, and aims to provide efficient and cost-effective manufacturing services for cell therapies. Cellares stands out by combining development and manufacturing processes under one roof, making it a competitive option in the industry.
South San Francisco, CaliforniaHeadquarters
2019Year Founded
$345.3MTotal Funding
SERIES_CCompany Stage
Industrial & Manufacturing, BiotechnologyIndustries
201-500Employees
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Stock Options
Risks
Emerging biotech startups threaten Cellares' market share with similar solutions.
Potential regulatory delays could impact scaling of new automated systems like Cell Q.
Supply chain vulnerabilities may disrupt production timelines for Cell Shuttle and Cell Q.
Differentiation
Cellares' Cell Shuttle offers 10x scalability over manual cell therapy manufacturing.
The Smart Factory technology integrates development and manufacturing, unlike traditional CDMOs.
Cell Q automates QC processes, addressing bottlenecks in cell therapy quality control.
Upsides
Partnership with Sony enhances precision in cell therapy manufacturing processes.
Strategic partnership with Bristol Myers Squibb provides financial boost and validation.
Ossama Eissa's appointment as COO accelerates global expansion and operational capabilities.
Funding
Total raised$345.32 M
Latest valuation$1.27 B
StageSERIES_C
SERIES C
7/31/2023$255
$1.27 BSERIES B
4/30/2021$82
$410.00 MSERIES A
9/30/2020$18
$90.00 M